CLINICAL_TRIALS
trial_result
· 2017-07-07
Clinical Trial Update: 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients [Phase 3]
Summary
A 12-month open-label long-term safety study of TNX-102 SL tablets in fibromyalgia patients (Phase 3) with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: Primary Fibromyalgia | Phase 3 | Status: COMPLETED | Results posted: 2017-07-07